Research & Development Team, National Prescribing Service, Level 7, 418a Elizabeth St, Surry Hills, NSW 2012, Australia.
BMC Health Serv Res. 2012 Aug 23;12:273. doi: 10.1186/1472-6963-12-273.
Research literature consistently documents that scientifically based therapeutic recommendations are not always followed in the hospital or in the primary care setting. Currently, there is evidence that some general practitioners in Australia are not prescribing appropriately for patients diagnosed with 1) hypertension (HT) and 2) chronic heart failure (CHF). The objectives of this study were to improve general practitioner's drug treatment management of these patients through feedback on their own prescribing and small group discussions with peers and a trained group facilitator. The impact evaluation includes quantitative assessment of prescribing changes at 6, 9, 12 and 18 months after the intervention.
A pragmatic multi site cluster RCT began recruiting practices in October 2009 to evaluate the effects of a multi-faceted quality improvement (QI) intervention on prescribing practice among Australian general practitioners (GP) in relation to patients with CHF and HT. General practices were recruited nationally through General Practice Networks across Australia. Participating practices were randomly allocated to one of three groups: two groups received the QI intervention (the prescribing indicator feedback reports and small group discussion) with each group undertaking the clinical topics (CHF and HT) in reverse order to the other. The third group was waitlisted to receive the intervention 6 months later and acted as a "control" for the other two groups.De-identified data on practice, doctor and patient characteristics and their treatment for CHF and HT are extracted at six-monthly intervals before and after the intervention. Post-test comparisons will be conducted between the intervention and control arms using intention to treat analysis and models that account for clustering of practices in a Network and clustering of patients within practices and GPs.
This paper describes the study protocol for a project that will contribute to the development of acceptable and sustainable methods to promote QI activities within routine general practice, enhance prescribing practices and improve patient outcomes in the context of CHF and HT.
Australian New Zealand Clinical Trials Registry (ANZCTR), Trial # 320870.
研究文献一致表明,在医院或初级保健环境中,并非总是遵循基于科学的治疗建议。目前有证据表明,澳大利亚的一些全科医生对诊断为 1)高血压(HT)和 2)慢性心力衰竭(CHF)的患者的药物治疗并不合理。本研究的目的是通过对自身处方的反馈以及与同行和经过培训的小组协调员进行小组讨论,改善全科医生对这些患者的药物治疗管理。影响评估包括在干预后 6、9、12 和 18 个月对处方变化的定量评估。
一项实用的多地点群组 RCT 于 2009 年 10 月开始招募实践单位,以评估多方面质量改进(QI)干预措施对澳大利亚全科医生(GP)与 CHF 和 HT 患者相关处方实践的影响。全科医生实践单位通过澳大利亚各地的全科医生网络在全国范围内招募。参与的实践单位被随机分配到三个组之一:两组接受 QI 干预(处方指标反馈报告和小组讨论),每组以与另一组相反的顺序进行临床主题(CHF 和 HT)。第三组被列入候补名单,在 6 个月后接受干预,并作为其他两组的“对照”。在干预前后每六个月提取实践、医生和患者特征及其对 CHF 和 HT 的治疗的去识别数据。使用意向治疗分析和考虑网络中实践的聚类以及实践内和 GP 内患者的聚类的模型,对干预组和对照组进行后测比较。
本文介绍了一个项目的研究方案,该项目将有助于开发在常规全科医疗中促进 QI 活动的可接受和可持续方法,增强处方实践并改善 CHF 和 HT 背景下的患者结果。
澳大利亚新西兰临床试验注册(ANZCTR),试验 #320870。